ArticleJCEM case reports2025
Suspected Central Adrenal Insufficiency in a Patient with Phosphomannomutase 2-Congenital Disorder of Glycosylation.
Article in JCEM case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG) is a hereditary defect causing hypoglycosylation of N-linked glycoproteins. It was recently suggested that patients with PMM2-CDG may have central adrenal insufficiency. We present an 18-year-old male with PMM2-CDG, whose initial screening suggested adrenal insufficiency. The patient displayed a morning plasma cortisol of 57 nmol/L (2.07 μg/dL) (reference range, 133-537 nmol/L [4.82-19.46 μg/dL]), a 30-minute ACTH-stimulated cortisol of 165 nmol/L (5.98 μg/dL), and a low-normal ACTH. The patient never experienced obvious symptoms of adrenal insufficiency nor clinical improvement after transient introduction of hydrocortisone. Additional assessment was therefore conducted, including cortisol binding globulin, which was markedly low (253 mmol/L (14.7 mg/L) (reference range, 750-2500 mmol/L [43.7-93.1 mg/L])). Subsequently, 8 Am salivary cortisol measured 24 hours after last hydrocortisone ingestion was normal-to-slightly elevated (38 nmol/L (1.38 μg/dL) (reference range, 2.48-29 nmol/L [0.09-1.05 μg/dL])). In conclusion, we present a patient with PMM2-CDG who, upon measurement of plasma cortisol, displayed "biochemical" adrenal insufficiency, although with low cortisol binding globulin and normal morning salivary free cortisol levels. This case illustrates the caveats of total cortisol for the diagnosis of adrenal insufficiency in patients with PMM2-CDG and highlights the potential impact of N-linked hypoglycosylation on endocrine evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.